Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulka Vaishampayan

Showing results (91-100 of 176) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancerRonald M Bukowski, Fairooz F Kabbinavar, Robert A Figlin, et al.
Investigational New Drugs|November 20, 2015
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) studyManish K Thakur, Lance K Heilbrun, Shijie Sheng, et al.
Cancer|July 29, 2010
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinomaToni K Choueiri, Zita Dubauskas Lim, Michelle S Hirsch, et al.
European Urology|April 21, 2023
Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell CarcinomaBrittney H Cotta, Toni K Choueiri, Marcin Cieslik, et al.
JCO Precision Oncology|July 6, 2023
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene AlterationsDeborah B Doroshow, Peter H O'Donnell, Jean H Hoffman-Censits, et al.
The Journal of Urology|October 22, 2008
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladderDavid C Smith, Niklas J Mackler, Rodney L Dunn, et al.
European Urology|February 3, 2012
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 TrialCamillo Porta, Emiliano Calvo, Miguel A Climent, et al.
European Journal of Radiology Open|September 12, 2022
Feasibility of using CT radiomic signatures for predicting CD8-T cell infiltration and PD-L1 expression in renal cell carcinomaBino Varghese, Steven Cen, Haris Zahoor, et al.
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancerElisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Pageof 18

Showing results (91-100 of 176) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancerRonald M Bukowski, Fairooz F Kabbinavar, Robert A Figlin, et al.
Investigational New Drugs|November 20, 2015
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) studyManish K Thakur, Lance K Heilbrun, Shijie Sheng, et al.
Cancer|July 29, 2010
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinomaToni K Choueiri, Zita Dubauskas Lim, Michelle S Hirsch, et al.
European Urology|April 21, 2023
Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell CarcinomaBrittney H Cotta, Toni K Choueiri, Marcin Cieslik, et al.
JCO Precision Oncology|July 6, 2023
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene AlterationsDeborah B Doroshow, Peter H O'Donnell, Jean H Hoffman-Censits, et al.
The Journal of Urology|October 22, 2008
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladderDavid C Smith, Niklas J Mackler, Rodney L Dunn, et al.
European Urology|February 3, 2012
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 TrialCamillo Porta, Emiliano Calvo, Miguel A Climent, et al.
European Journal of Radiology Open|September 12, 2022
Feasibility of using CT radiomic signatures for predicting CD8-T cell infiltration and PD-L1 expression in renal cell carcinomaBino Varghese, Steven Cen, Haris Zahoor, et al.
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancerElisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Pageof 18